About 14 results found for searched term "PKD" (0.123 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M27926 | BPKDi | PKD |
| BPKDi is a potent bipyridyl PKD inhibitor with IC50s of 1 nM, 9 nM and 1 nM for PKD1, PKD2 and PKD3, respectively. BPKDi blocks signal-dependent phosphorylation and nuclear export of class IIa HDACs in cardiomyocytes. | ||
| M2556 | CID-2011756 | PKD |
| CID-2011756 is a cell-active ATP competitive and specific PKD1 inhibitor that inhibits phorbol ester-induced endogenous PKD1 activation in LNCaP prostate cancer cells. | ||
| M3747 | CID755673 | PKD |
| CID755673 is a potent and selective cell-active small molecule inhibitor for PKD with an IC50 of 182 nM. | ||
| M6635 | CRT0066101 dihydrochloride | PKD |
| CRT 0066101 is a potent protein kinase D (PKD) inhibitor. | ||
| M8382 | kb-NB142-70 | Others |
| kb-NB142-70 is a derivative of the PKD1 inhibitor CID755673, with approximately 6-fold greater potency (IC50 for inhibition of PKD1 = 28. | ||
| M20584 | kb-NB77-78 | Others |
| kb-NB77-78 is an analog of CID797718. However, it shows no inhibitory activty towards PKD1. | ||
| M21511 | RGLS4326 | Others |
| RG4326 | ||
| RGLS4326 (RG4326) is a first-in-class microRNA-17 (miR-17) oligonucleotide inhibitor. RGLS4326 can be used in the study of autosomal dominant polycystic kidney disease (ADPKD). RGLS4326 acts on HeLa cells to inhibit the function of miR-17 with EC50 value of 28.3 nM. | ||
| M29070 | Methiothepin maleate | 5-HT Receptor |
| Metitepine maleate; Ro-8-6837 maleate | ||
| Methiothepin maleate is a potent and non-selective 5-HT2 receptor antagonist, with pKds of 7.10 (5-HT1A), 7.28 (5HT1B), 7.56 (5HT1C), 6.99 (5HT1D), 7.0 (5-HT5A), 7.8 (5-HT5B), 8.74 (5-HT6), and 8.99 (5-HT7), and pKis of 8.50 (5HT2A), 8.68 (5HT2B), and 8.35 (5HT2C). | ||
| M29089 | GSK8814 | Epigenetic Reader Domain |
| GSK8814 is a potent, selective, and ATAD2/2B bromodomain chemical probe and inhibitor, with a binding constant pKd=8.1 and a pKi=8.9 in BROMOscan. GSK8814 binds to ATAD2 and BRD4 BD1 with pIC50s of 7.3 and 4.6, respectively. GSK8814 shows 500-fold selectivity for ATAD2 over BRD4 BD1. | ||
| M29291 | GSK973 | Epigenetic Reader Domain |
| GSK973 is a highly selective, orally bioavailable inhibitor of the BD2s (second bromodomains) of the BET family, with a pIC50 of 7.8 and a pKd of 8.7 for BRD4 BD2. GSK973 displays a 1600-fold selectivity for BRD4 BD2 over BRD4 BD1. GSK973 shows good potency against BRD2 BD2, BRD3 BD2, and BRDT BD2 (pIC50=7.4~7.8; pKd=8.3~8.5). | ||
| M30457 | VQW-765 | AChR/AChE |
| AQW-051 | ||
| VQW-765 (AQW-051) is a selective and orally active alpha-7 nicotinic acetylcholine receptor (α7-nAChR) agonist with a pKD value of 7.56 to recombinantly expressed human α7-nAChR. VQW-765 shows anxiolytic-like effect in vivo. VQW-765 can be used for the research of anxiety disorder and acute performance anxiety. | ||
| M41878 | Atilmotin | Others |
| OHM 11638 (Atilmotin), an analogue of the (1-14) fragment of porcine motilin, is a motilin receptor agonist with a pKd of 8.94 for the motilin receptor. | ||
| M53075 | ANQ-11125 | Others |
| ANQ-11125 is a potent and selective antagonist of motilin, with the pKd of 8.24. | ||
| M54808 | VX-407 | PKD |
| VX407 | ||
| VX-407 is a first-in-class small molecule corrector that targets the underlying cause of ADPKD in a subset with responsive PKD1 mutations. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
